Regenxbio Inc. (NASDAQ:RGNX) has earned an average broker rating score of 1.13 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy rating and three have assigned a strong buy rating to the company.
Brokers have set a twelve-month consensus price objective of $30.50 for the company and are forecasting that the company will post ($0.60) EPS for the current quarter, according to Zacks. Zacks has also assigned Regenxbio an industry rank of 109 out of 265 based on the ratings given to its competitors.
A number of analysts have recently weighed in on RGNX shares. Zacks Investment Research upgraded shares of Regenxbio from a “hold” rating to a “buy” rating and set a $8.75 target price for the company in a report on Wednesday, July 6th. Piper Jaffray Cos. restated a “buy” rating and issued a $33.00 price objective on shares of Regenxbio in a report on Tuesday, July 5th. Finally, Chardan Capital restated a “buy” rating on shares of Regenxbio in a report on Monday, August 22nd.
Hedge funds have recently modified their holdings of the company. Nationwide Fund Advisors increased its position in shares of Regenxbio by 196.1% in the second quarter. Nationwide Fund Advisors now owns 12,815 shares of the company’s stock worth $103,000 after buying an additional 8,487 shares in the last quarter. Metropolitan Life Insurance Co. NY acquired a new position in shares of Regenxbio during the second quarter worth $136,000. Rhumbline Advisers acquired a new position in shares of Regenxbio during the second quarter worth $148,000. A.R.T. Advisors LLC acquired a new position in shares of Regenxbio during the second quarter worth $220,000. Finally, Strs Ohio increased its position in shares of Regenxbio by 19.6% in the second quarter. Strs Ohio now owns 29,600 shares of the company’s stock worth $236,000 after buying an additional 4,859 shares in the last quarter. Institutional investors and hedge funds own 68.73% of the company’s stock.
Regenxbio (NASDAQ:RGNX) opened at 16.02 on Friday. Regenxbio has a 52 week low of $7.07 and a 52 week high of $25.00. The stock has a 50 day moving average price of $14.36 and a 200-day moving average price of $11.40. The stock’s market cap is $423.97 million.
Regenxbio (NASDAQ:RGNX) last posted its earnings results on Tuesday, August 9th. The company reported ($0.55) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.53) by $0.02. Regenxbio had a negative return on equity of 17.89% and a negative net margin of 451.73%. On average, equities analysts anticipate that Regenxbio will post ($2.37) EPS for the current fiscal year.
REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).